Vantage uses cookies that are essential for our website to work. We also use optional analytical cookies to help us to improve our website and the services, content and ads we provide to you which you can accept or reject here. Please see our Cookies Policy for more information on how we use cookies.
CFDs and Spread Bets are complex instruments and come with a high risk of losing money rapidly due to leverage. 73.5% of retail investor accounts lose money when trading CFDs and Spread Bets with this provider. You should consider whether you understand how CFDs and Spread Bets work and whether you can afford to take the high risk of losing your money. Please seek independent advice if necessary.
Is demand for the Covid-19 vaccine fading? If yes, what could investors expect from Moderna Inc. during its earnings call? The Covid-19 vaccine maker is set to release its quarterly earnings results on Thursday, November 3, 2022.
How has Moderna performed so far?
Moderna was among the hottest stocks in the market when the virus emerged. The company became one of the top winners in the race to develop a vaccine. The company’s stock rallied around 2,500% from the time of its IPO in December 2018 to July 2021. However, it has been a completely different story for the drug maker since that time, with demand for Covid-19 vaccines fading in recent times.
The US and other countries around the world are seeing a decline in vaccination rates and fears over the severity of Covid-19 have also declined. These factors are expected to negatively impact Moderna and other vaccine maker stocks going forward. However, with some experts predicting another Covid-19 wave in the fall and winter, and Moderna developing a booster dose for the Omicron variant and a combination Covid-19/flu vaccine, the stock could see better days ahead.
What’s expected from Moderna for Q3?
Moderna last reported its quarterly earnings results on August 3 with its EPS of $5.24 beating analyst expectations of $4.50. Its revenue of $4.73 billion also came in above the market estimates of $3.95 billion.
Analysts, on average, are expecting the company to report quarterly earnings of $3.76 per share on revenue of $3.88 billion. Analysts at Jefferies Financial Group recently reduced their Q3 earnings estimates for Moderna. Jefferies analyst M. Yee now sees earnings of $1.77 per share, down from the earlier forecast of $4.32 per share.
How to trade Moderna’s earnings report
If the company’s earnings disappoint the market, the stock could face volatility. One way to protect yourself against such single-stock volatility is to invest in ETFs CFDs. ETFs invest in a basket of stocks from a particular sector or attempt to replicate an index. This means that you can diversify your portfolio with a single investment.
Trade earnings-driven market moves with Vantage. Open a RAW ECN account and start trading with spreads from 0.0 pips.
Fast & easy account opening
-
Register
Choose an account type and submit your application
-
Fund
Fund your account using a wide range of funding methods.
-
Trade
Access 1000+ CFD instruments across all asset classes on MT4
About us
Vantage is a global, multi-asset broker offering clients access to a nimble and powerful service for trading CFDs on Forex, Commodities, Indices, Shares.
With more than 10 years of market experience and headquartered in Sydney, Vantage now has over 1,000 staff across more than 30 global offices.
Vantage is more than a broker. It provides a trusted trading ecosystem that enables clients to achieve their own success, in a faster and simpler manner.
Empowering you to better trade on the right market opportunities. trade smarter @vantage.
